HR-8358-119
Referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and Commerce, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Beth Van Duyne (R-TX)
What it does
This bill would extend the U.S. Postal Service's authority to sell a "semipostal" stamp — a stamp sold at a price above its face postage value — dedicated to raising funds for breast cancer research. It would push the program's expiration date from 2027 to 2037, a ten-year extension. The extra amount paid above the postage rate is directed to breast cancer research funding.
Who benefits
Breast cancer researchers and the institutions that receive funding generated by stamp sales. Breast cancer patients and those at risk who may benefit from advances in research. The Department of Defense and National Institutes of Health, which have historically received funds from the stamp program. Stamp collectors and members of the public who wish to contribute to breast cancer research through routine mail purchases. The USPS, which retains a small administrative portion of the surcharge.
Who is hurt
There are no direct, identifiable groups who are materially harmed by this bill. Researchers or organizations focused on other diseases may face indirect competition for philanthropic attention, though the stamp program does not redirect existing federal appropriations away from other health priorities. Taxpayers bear minimal administrative costs associated with USPS program management.
Supporters argue
Supporters argue that the Breast Cancer Research Stamp has raised over $100 million for research since its creation in 1998, providing a proven, low-cost mechanism for voluntary public contributions that supplements — rather than replaces — direct federal appropriations. They contend that extending the program through 2037 ensures continuity of a popular, bipartisan initiative that imposes no tax burden and allows individuals to direct a small personal contribution toward a major public health cause affecting roughly 1 in 8 American women.
Opponents argue
Opponents argue that the federal government should not use the postal system to selectively channel voluntary surcharges toward one disease category, however worthy, when many other conditions — such as heart disease, Alzheimer's, or lung cancer — cause comparable or greater mortality without similar dedicated funding mechanisms. They contend that repeated reauthorizations entrench a piecemeal, disease-by-disease approach to research funding that bypasses the normal appropriations process and may distort research priorities relative to evidence-based need.
Constitutional context
No significant constitutional issue is presented. Congress has broad authority under the Postal Clause (Art. I, §8, cl. 7) and the Taxing and Spending Clause (Art. I, §8, cl. 1) to direct USPS operations and designate the use of voluntarily collected surcharges. No active constitutional challenge or doctrinal tension applies to this type of legislation.
Checks and balances
Congress sets the program's authorization period and funding recipients; the USPS administers stamp sales and surcharge collection; the Departments of Defense and Health and Human Services oversee distribution of research funds, subject to existing appropriations law oversight.
Historical precedent
The original Breast Cancer Research Stamp was authorized by the Stamp Out Breast Cancer Act of 1997 and has been reauthorized multiple times, most recently extending the program to 2027; this bill follows the same reauthorization pattern.